betaxolol hydrochloride
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
96
Go to page
1
2
3
4
November 25, 2025
Engineered Multifunctional Drug-Loaded Dendrimer Nanoparticles for Glaucoma: Triple Mechanism via Antioxidant Activity, Iron Chelation, and Enhanced Ocular Transport.
(PubMed, Biomacromolecules)
- "In this study, we developed multifunctional nanoparticles based on polyamidoamine (PAMAM) dendrimers functionalized with caffeic acid (CA) and poly(ethylene glycol) maleimide (PEGM) for the topical delivery of hydrophobic antiglaucoma drugs brimonidine (BM) and betaxolol (BX). Both PAMAM-CA and PAMAM-CA-PEGM nanoparticles exhibited concentration-dependent antioxidant activity comparable to that of CA. These findings suggest the potential of this multifunctional dendrimer-based nanoparticle system as an innovative strategy for glaucoma medication."
Journal • Glaucoma • Ophthalmology
October 24, 2025
Evaluation of betaxolol in improving the glasgow outcome scale extended (GOSE) of the acute phase of patients with mild to moderate Traumatic Brain Injury: a double blinded randomized clinical trial.
(PubMed, Neurol Res)
- "Betaxolol was well-tolerated but these findings do not support its efficacy for routine use in acute mild-to-moderate TBI. Further studies with larger sample sizes and longer follow-up are needed for conclusive evaluation."
Clinical • Journal • CNS Disorders • Vascular Neurology
July 31, 2025
Cationic separation of medium strong bases by electrophoretic focusing on inverse electromigration dispersion profile. Sensitive analysis of beta-blockers in blood and water with ESI-MS detection.
(PubMed, J Chromatogr A)
- "The method allows direct injection of aqueous dried blood spot extracts and sensitive determination of metoprolol and betaxolol in real samples with limits of detection at the 2 nM (500 ngL-1) level. Experiments with direct injection of spiked water samples show that the method can be used also for analysis of beta-blockers in waters with almost the same sensitivity."
Journal
June 21, 2025
Effects of taurine, brimonidine and betaxolol on oscillation modulation and stimulation efficiency in degenerated rd10 mouse retinas.
(PubMed, Sci Rep)
- "The drugs tested appear to be promising therapeutic candidates for improving the residual function of RGCs. They will be further investigated and combined with other RP treatments, such as retinal prostheses, in the future."
Journal • Preclinical • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa
June 14, 2025
Cat scratch disease: ocular manifestations
(SOE 2025)
- "Initial therapy was Agapurin, Milgamma, Betaxolol drops and Nurofen...Dexamethasone, Dorzolamide, Timolol and Bromfenac eye drops were added... Cat scratch disease is an infectious illness primarily caused by the bacterium Bartonella henselae, commonly transmitted through scratches or bites from infected cats. While typically characterized by swollen lymph nodes, it can present with diverse range of symptoms. Ocular manifestations can serve as the sole or initial presentation of the disease."
Ophthalmology
April 27, 2025
Drugs for open-angle glaucoma.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Glaucoma • Ophthalmology
April 06, 2025
Enhanced ocular retention and intraocular pressure-lowering efficacy of hydrophobic microspheres for glaucoma treatment.
(PubMed, Colloids Surf B Biointerfaces)
- "This study aimed to address these challenges by developing betaxolol hydrochloride-loaded mesoporous silica polyacrylic resin microspheres (BH@MCM-41 MPs) and comparing their safety, ocular retention, and intraocular pressure (IOP)-lowering efficacy with previously reported betaxolol hydrochloride-loaded montmorillonite polyacrylic resin microspheres (BH@MMT MPs), BH solution, and commercially available Betoptic®...The area under the IOP reduction curve (AUC0-36h) for BH@MCM-41 MPs was 1.2-fold greater than for BH@MMT MPs, and significantly higher than for the BH solution and Betoptic. These findings suggest that BH@MCM-41 MPs offer enhanced efficacy for sustained glaucoma treatment through improving precorneal retention."
Journal • Glaucoma • Ophthalmology
March 13, 2025
The Effectiveness of Liquid-Phase Microextraction of Beta-Blockers from Aqueous Matrices for Their Analysis by Chromatographic Techniques.
(PubMed, Molecules)
- "The aim of this research is to test the effectiveness of two green liquid-phase microextraction procedures, such as dispersive liquid-liquid microextraction (DLLME) and solidification of floating organic droplet microextraction (SFOME) for the selective extraction of eight beta-blockers (atenolol, nadolol, pindolol, acebutolol, metoprolol, bisoprolol, propranolol, and betaxolol) from aqueous matrices for their analysis by gas chromatography (GC) or liquid chromatography (LC). Good limits of detection (0.13 to 0.69 µg/mL for GC and 0.07 to 0.15 µg/mL for HPLC) and limits of quantification (0.39 to 2.10 µg/mL for GC and 0.20 to 0.45 µg/mL for LC) were obtained. The developed procedures were successfully applied to the analysis of selected beta-blockers in wastewater samples, proving their applicability to the real samples."
Journal • Cardiovascular • Hypertension
January 22, 2025
Restraint stress effects on glutamate signaling protein levels in the rats' frontal cortex: Does β1 adrenoceptor activity matter?
(PubMed, Front Pharmacol)
- "In the current study, we adopted a restraint stress (RS) model in male Wistar rats to investigate whether the blockade of β1 adrenergic receptors (β1AR) with betaxolol (BET) in stressed animals influences the body's stress response and the expression of selected signaling proteins in the medial prefrontal cortex (mPFC)...β1AR blockade normalized only the blood concentration of ACTH. These results suggest that decreased Fyn kinase activity, indicated by phosphorylation at Y530, underlies the stress-evoked downregulation of GluN2B in the FC in a manner independent of β1AR activity."
Journal • Preclinical • FYN • GRIN2B • SLC2A1
November 04, 2024
β-Blockers and Asthma: Surprising Findings from the FAERS Database.
(PubMed, Respir Med)
- "Risk stratification underscores the need for cautious β-blocker selection in asthmatic patients or those predisposed to asthma. The study highlights significant variability in risk among different β-blocker classes, crucial for clinical decisions and patient outcomes. Drugs like esmolol, metoprolol, nebivolol, and nadolol may be safer for asthmatic patients, whereas betaxolol, bisoprolol, timolol, and propranolol should be avoided. Regular respiratory monitoring is crucial for asthmatic patients on β-blockers, starting treatment at low doses and adjusting to minimize bronchoconstriction risk."
Journal • Asthma • Cardiovascular • Immunology • Pulmonary Disease • Respiratory Diseases
July 12, 2024
Spatiotemporal dynamics of reactive oxygen species and its effect on beta-blockers' degradation in aquatic plants' rhizosphere.
(PubMed, J Hazard Mater)
- "Through mass balance analysis and quenching experiment, we revealed that ROS contributed significantly to rhizodegradation for beta-blockers, ranging from 22.18 % for betaxolol to 83.83 % for atenolol. ROS production patterns were driven by rhizosphere chemistry (Fe and humic substances) and microbiome variations in different rhizocompartments. These findings not only deepen understanding of ROS production in aquatic plants rhizosphere but also shed light on advancing phytoremediation strategies."
Journal
June 14, 2024
Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy.
(PubMed, Adv Sci (Weinh))
- "Utilizing hydrophobic antiglaucoma drugs brimonidine (BM) and betaxolol (BX), uniform fixed combination BM/BX SDNs are fabricated through a continuous process, improving batch-to-batch consistency for combined glaucoma treatment. Notably, BM/BX SDNs displayed consistent intraocular pressure lowering effects in vivo in both normotensive rats and glaucoma mice. Collectively, this study demonstrates the potential of the scalable fabrication strategy and the resultant BM/BX SDNs for improving glaucoma management through eyedrops."
Journal • Cardiovascular • Glaucoma • Ophthalmology
May 29, 2024
Sex differences in hippocampal β-adrenergic receptor subtypes drive retrieval, retention, and learning of cocaine-associated memories.
(PubMed, Front Behav Neurosci)
- "Rats were infused directly to the dorsal hippocampus with Propranolol (β1 and β2) or ICI-118,551 (β1) and/or Betaxolol (β2), immediately prior to testing (retrieval), or paired to each cocaine (10 mg/kp, IP) conditioning session (learning). Furthermore, sub regions of the dorsal hippocampus appear to activate differently between male and female rats during CPP. Therefore DG, CA3, and CA1 may have separate region- and sex-specific impacts on driving drug- associated, or context-associated cues."
Journal • CA3
May 21, 2024
Drugs for hypertension.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Review • Cardiovascular • Hypertension
May 18, 2024
Sex Differences in Contextual Cocaine Seeking Behavior are Driven by Noradrenergic Signaling to the Dorsal Hippocampus
(CPDD 2024)
- "We administered β-AR antagonists (Betaxolol (β1) and/or ICI 118,551 (β2)) to the dHPC prior to retrieval in both CPP and CSP... There are significant sex differences in the role of dorsal hippocampus β-ARs in the encoding and expression of both Pavlovian and operant cocaine memories. Furthermore, these effects may be driven by sex differences in adrenergic tone between the locus coeruleus and dorsal hippocampus. Thus, the substantial sex differences in the retrieval and retention of cocaine memories may be driven in part by adrenergic signaling."
CNS Disorders
May 08, 2024
LC and LC-MS/MS Studies for the Separation and Identification of Impurities and Degradation Products of Betaxolol.
(PubMed, J Chromatogr Sci)
- "Based on LC-ESI/MS analysis, the found results revealed that Bx decomposes in acidic, basic and oxidizing environments. All degradation products were identified with the help of their fragmentation pattern and the masses obtained upon the MS analysis."
Journal • Cardiovascular • Glaucoma • Hypertension • Ophthalmology
February 08, 2024
Different concentrations of betaxolol switch cell fate between necroptosis, apoptosis, and senescence in human corneal stromal cells.
(PubMed, Chem Biol Interact)
- "Finally, clinical concentrations of betaxolol had a pro-apoptotic effect on rabbit corneal stromal cells in vivo. These results suggest that betaxolol induces cytotoxicity in a concentration-dependent manner in HCSCs, and that caspase-8 and Bcl-2 family proteins may be critical switches in the conversion of different HCSC death mechanisms."
IO biomarker • Journal • Stroma • Corneal Abrasion • Glaucoma • Ophthalmology • BCL2 • BCL2L1 • CASP8 • CASP9 • RIPK1
October 20, 2023
Paternal methamphetamine exposure induces higher sensitivity to methamphetamine in male offspring through driving ADRB1 on CaMKII-positive neurons in mPFC.
(PubMed, Transl Psychiatry)
- "Selective antagonist (betaxolol) for β1-adrenergic receptor (ADRB1) or its knocking-down virus were administrated into mPFC to regulate ADRB1 function and expression on CaMKII-positive neurons. In the process, the p-ERK1/2 and ΔFosB may be potential subsequent signals of mPFC ADRB1. The mPFC ADRB1 mediates paternal METH exposure-induced higher sensitivity to drug addiction in male offspring, raising a promising pharmacological target for predicting or treating transgenerational addiction."
Journal • CNS Disorders • Psychiatry • Substance Abuse
September 09, 2023
Betaxolol as a Potent Inhibitor of NDM-1-Positive E. coli That Synergistically Enhances the Anti-Inflammatory Effect in Combination with Meropenem.
(PubMed, Int J Mol Sci)
- "Molecular docking and kinetic simulations showed that BET can form hydrogen bonds and hydrophobic interactions directly with key amino acid residues in the NDM-1 active site. Thus, we demonstrated that BET inhibited NDM-1 by competitively binding to it and that it can be developed in combination with MEM as a new therapy for the management of infections caused by medicine-resistant bacteria."
Combination therapy • Journal • Glaucoma • Infectious Disease • Ophthalmology
July 29, 2023
MXene nanosheets woven in polyacrylonitrile nanofiber yarns aligned spider web as a highly efficient sorbent for in-tube solid phase microextraction of beta-blockers from biofluids.
(PubMed, J Chromatogr A)
- "The inter- and intra-assay precisions (RSDs, for n = 3) are in the range of 2.5-3.5%, and 4.5-5.2%, respectively. Finally, the validated method was put in an application for the analysis of atenolol, propranolol and betaxolol in human urine and saliva samples at different hours and acceptable relative recoveries were obtained in the range of 89.5% to 110.4%."
Journal
July 03, 2023
Impact of Beta-blockers on Physical Function in HFpEF
(clinicaltrials.gov)
- P4 | N=9 | Completed | Sponsor: Weill Medical College of Cornell University | Recruiting ➔ Completed | N=16 ➔ 9 | Trial completion date: Sep 2023 ➔ Apr 2023
Enrollment change • Trial completion • Trial completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
June 18, 2023
Microextraction by packed sorbent of some β-blocker drugs with chitosan@mof-199 bio-composite in human saliva, plasma, and urine samples.
(PubMed, J Pharm Biomed Anal)
- "The current study introduces microextraction by packed sorbent (MEPS) to extract three beta-blocker drugs (propranolol, atenolol, and betaxolol) from biological samples. The results showed that the highest amount of propranolol is released 4 h after taking the drug. Based on the obtained results, this is an effective, fast, sensitive, reproducible, green, and user-friendly method for beta-blocker drug extraction in biological samples."
Journal
May 11, 2023
Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF
(clinicaltrials.gov)
- P4 | N=9 | Completed | Sponsor: Weill Medical College of Cornell University | Active, not recruiting ➔ Completed | Trial completion date: Oct 2023 ➔ Apr 2023 | Trial primary completion date: Oct 2023 ➔ Apr 2023
Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
May 05, 2023
Longterm Impact of Immediate Versus Delayed Treatment of Early Glaucoma Results from the Early Manifest Glaucoma Trial.
(PubMed, Am J Ophthalmol)
- "Delaying treatment did not result in serious penalties. VI occurred at similar proportions in both treatment arms with a slight preponderance in the treatment group, while visual field damage was slightly higher in the control group."
Clinical • Journal • Glaucoma • Ophthalmology
April 27, 2023
The role of beta- and alpha-adrenergic receptors on alcohol drinking.
(PubMed, Neuropharmacology)
- "Betaxolol (2.5 mg/kg) also decreased drinking, while ICI 118.551 had no effects...Here, a combination of ineffective doses of propranolol and prazosin reduced both CLAD and AOD...Surprisingly, propranolol (1-10 μg) in aINS or mPFC did not affect CLAD or AOD. Together, our findings provide new pharmacological insights into noradrenergic regulation of alcohol consumption, which may inform AUD therapy."
Journal • Addiction (Opioid and Alcohol)
1 to 25
Of
96
Go to page
1
2
3
4